About 705 results

ALLMedicine™ Adult-onset Still's Disease Center

Research & Reviews  269 results

Short-term, low-dose etoposide in refractory adult-onset Still's disease-associated mac...
https://doi.org/10.1007/s10067-022-06184-1 10.1016/j.autrev.2014.01.058 10.1097/MD.0000000000004258 10.1016/j.rmcr.2017.07.001 10.1186/s12969-016-0130-4 10.1016/j.berh.2014.03.002[publishedOnlineFirst:2014/06/30] 10.1002/art.38672 10.1146/annurev-med-061813-012806 10.1155/2016/3717392 10.1155/2016/5656320 10.2147/TCRM.S195538[publishedOnlineFirst:2021/04/24] 10.1182/blood.2019002289[publishedOnlineFirst:2019/09/21] 10.1136/annrheumdis-2018-213920[publishedOnlineFirst:2018/10/04] 10.1016/S2352-3026(19)30156-5[publishedOnlineFirst:2019/09/21] 10.1016/j.jaip.2018.05.031[publishedOnlineFirst:2018/09/12] 10.1002/pbc.21039 10.1182/blood-2011-06-356261[publishedOnlineFirst:2011/09/09] 10.1182/blood.2018894618[publishedOnlineFirst:2019/04/18] 10.1097/00043426-200210000-00011 10.1097/MPH.0b013e3181923cb4 10.1056/NEJMoa1911326[publishedOnlineFirst:2020/05/07] 10.1182/blood-2002-01-0172[publishedOnlineFirst:2002/09/20] 10.1182/blood-2011-03-278127[publishedOnlineFirst:2011/08/11] 10.1002/art.39332 10.3899/jrheum.161286 10.1016/j.jpeds.2013.06.053 10.2147/TCRM.S64951 10.1007/s10067-020-04949-0[publishedOnlineFirst:2020/03/05] 10.4049/jimmunol.1302282[publishedOnlineFirst:2013/11/22]
Clinical Rheumatology; Wang R, Li T et. al.

May 20th, 2022 - In this study, we modified the classical regimen of the hemophagocytic lymphohistiocytosis-04 protocol and evaluated the efficacy and safety of short-term, low-dose etoposide in patients with refractory macrophage activation syndrome (MAS) associa...

Adult-onset Still's disease with elderly onset, results from a multicentre study.
Clinical and Experimental Rheumatology; Di Cola I, Di Muzio C et. al.

May 18th, 2022 - In this study, we aimed at describing the clinical characteristics, life-threatening complications occurrence, and mortality of adult-onset Still's disease (AOSD) patients with elderly onset. A multicentre retrospective study of prospectively foll...

The hyper-expression of NLRP4 characterizes the occurrence of macrophage activation syn...
Clinical and Experimental Immunology; Ruscitti P, Berardicurti O et. al.

May 14th, 2022 - To assess stimulator of interferon genes (STING) pathway in patients with adult-onset Still's disease (AOSD) who were complicated or not by macrophage activation syndrome (MAS), evaluating peripheral blood mononuclear cells (PBMCs), and synovial t...

Immune transcriptome and antibody response in adult-onset Still's disease with mild fla...
Rheumatology (Oxford, England); Knabl L, Lee HK et. al.

May 10th, 2022 - Immune transcriptome and antibody response in adult-onset Still's disease with mild flare following administration of mRNA vaccine BNT162b2.|2022|Knabl L,Lee HK,Walter M,Furth PA,Hennighausen L,|

Macrophage activation syndrome in rheumatic disease: Clinical characteristics and progn...
PloS One; Nam SH, Ahn SM et. al.

May 7th, 2022 - Macrophage activation syndrome (MAS) is a hyperinflammatory condition that is known to be secondary hemophagocytic lymphohistiocytosis (HLH) in patients with rheumatic disease. The aim of study was to evaluate the clinical manifestations and outco...

see more →

Clinicaltrials.gov  4 results

Treatment of Macrophage Activation Syndrome (MAS) With Anakinra

Jan 4th, 2022 - Macrophage activation syndrome (MAS) is a disorder whereby the immune system generates very high levels of substances (cytokines) that promote inflammation to the extent dysfunction occurs in multiple organ systems which if unchecked, is frequentl...

Canakinumab for Treatment of Adult-onset Still's Disease

Aug 7th, 2020 - The purpose of this trial is to investigate the efficacy of the treatment with canakinumab in participants with Adult-onset Still's Disease (AOSD) and active joint involvement.

Tocilizumab in Patients With Schnitzler's Syndrome

Feb 17th, 2020 - Schnitzler's Syndrome (SchS) is a late-onset multifactorial autoinflammatory disease characterized by chronic urticarial skin lesions and a monoclonal gammopathy usually belonging to the immunoglobulin M (IgM) or IgG class. Symptoms associated wit...

Therapeutic Use of Tadekinig Alfa in Adult-onset Still's Disease

Dec 6th, 2016 - The hypothesis of this study considers high levels of IL-18 during active Adult-onset still's disease as the therapeutic target. Treatment with IL-18BP will permit to inhibit the pro-inflammatory cascade triggered by IL-18 and may help to manage t...

see more →

News  9 results

NICE Recommends Anakinra for Paediatric and Adult-onset Still’s Disease

Apr 1st, 2021 - The National Institute for Health and Care Excellence (NICE) has recommended anakinra (Kineret, Swedish Orphan Biovitrum) as a treatment option for Still’s disease in adults and systemic juvenile idiopathic arthritis in children. Anakinra is an in...

FDA Approves Canakinumab (Ilaris), First Drug for Adult-Onset Still's Disease

Jun 19th, 2020 - The Food and Drug Administration has expanded the indications for canakinumab (Ilaris) to include all patients with active Still's disease older than 2 years, adding adult-onset Still's disease (AOSD) to a previous approval for juvenile-onset Stil...

Rheumatologists: On the COVID-19 Front Line

Mar 22nd, 2020 - Rheumatologists may be in a unique position to consult and help in the management of patients with severe disease caused by COVID-19, said experts. "Some of the drugs that appear promising for patients who are severely ill with COVID-19 are those ...

Lethal Lung Disease and Biologics: Is There a Link?

Sep 4th, 2019 - A new, potentially life-threatening parenchymal lung disease is increasingly being detected in patients with systemic juvenile idiopathic arthritis (sJIA), according to recent reports. Systemic JIA is distinct from other forms of JIA in that the a...

IL-6 for Adult Still's: A New Option?

Oct 14th, 2018 - Action Points Some clinical benefits were seen among patients with adult-onset Still's disease treated with tocilizumab (Actemra) in a small clinical trial, but the study's primary endpoint was not met. During the double-blind part of the trial, t...

see more →